Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05414162 | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | unknown | — | 60 | University Hospital, BonnOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | unknown | Phase 1 | 15 | Beijing Boren HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05406154 |
| Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years |
| unknown |
| — |
| 60 |
| Peking University Third HospitalOTHER |
| 1 |
| Jun 6, 2022 |
| clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05398614 | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies | unknown | Phase 1 | 18 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04928105 | Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma | unknown | N/A | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT05398224 | R-MTX-zanbrutinib in Secondary CNS Lymphoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05110950 | Endobronchial Ultrasound Needle Aspiration With and Without Suction | unknown | N/A | 306 | Università Politecnica delle MarcheOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT05385263 | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion | unknown | Phase 2 | 20 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | May 26, 2022 | clinicaltrials |
| NCT05390749 | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | unknown | Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05387226 | Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma | unknown | Phase 1 | 6 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT05381077 | Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner(MM-ZTE) | unknown | N/A | 30 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05379647 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02589548 | Brazilian Prospective Hodgkin Lymphoma Registry | unknown | — | 1,400 | Universidade Federal do Rio de JaneiroOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05374226 | A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 172 | Suzhou Kebo Ruijun Biotechnology Co., LtdINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT02623010 | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03958916 | Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL | unknown | — | 500 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03971305 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL | unknown | — | 300 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03971318 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL | unknown | — | 300 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04624984 | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | unknown | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05364177 | 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03671850 | VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients | unknown | Phase 2 | 48 | ViGenCell Inc.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04678089 | Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics | unknown | — | 350 | Beijing Chao Yang HospitalOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05350852 | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL | unknown | Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05277493 | A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab | unknown | — | 500 | Peking Union Medical College HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05349266 | Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy | unknown | Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05343676 | Different Sonographic Modalities and PET-CT in Pediatric Lymphoma | unknown | — | 45 | Assiut UniversityOTHER | 0 | Apr 25, 2022 | clinicaltrials |
| NCT05340829 | Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia | unknown | Phase 1 | 18 | He HuangOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05340985 | Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis | unknown | Phase 4 | 54 | Tehran University of Medical SciencesOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT03853044 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04480125 | Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | unknown | Phase 2 | 28 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05322733 | Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | unknown | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05334238 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | unknown | Phase 3 | 174 | Ruijin HospitalOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05286164 | Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART | unknown | Phase 2 | 30 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05331313 | The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma(MMSPORADGEN) | unknown | — | 1,000 | Hospices Civils de LyonOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05275036 | Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies(ASCEND-LYM) | unknown | — | 493 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05326984 | Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia | unknown | N/A | 20 | Hospital General de MexicoOTHER_GOV | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05325801 | A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 9 | Zhejiang UniversityOTHER | 0 | Apr 13, 2022 | clinicaltrials |
| NCT05320081 | Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma | unknown | Phase 2 | 30 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05320640 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04246359 | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma(RIPPLE) | unknown | Phase 2 | 52 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04514393 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | unknown | Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05093140 | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL(CREDIT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT04491825 | Diagnostic Classifier for Cutaneous T-cell Lymphomas | unknown | — | 160 | Medical University of ViennaOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03646422 | AEDV Registry of Primary Cutaneous Lymphoma | unknown | — | 2,000 | Fundación Academia Española de DermatologíaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05191225 | Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study | unknown | Phase 4 | 48 | Laida Cuevas PalomaresNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05147493 | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | unknown | Phase 2 | 51 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 15, 2022source: clinicaltrials